Want to see ENTX full AI Analyst Report?
ENTX Stock Chart & Stats
$3.47
-$0.08(-3.76%)
At close: 4:00 PM EDT
$3.47
-$0.08(-3.76%)
Day’s Range― - ―
52-Week Range$0.91 - $4.20
Previous CloseN/A
Volume163.47K
Average Volume (3M)608.30K
Market Cap
$497.42M
Enterprise Value$71.29M
Total Cash (Recent Filing)$11.31M
Total Debt (Recent Filing)$425.00K
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding173,922,420
10 Day Avg. Volume728,014
30 Day Avg. Volume608,304
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.75K
Enterprise Value/Ebitda-5.00
Forecast
1Y Price Target
$10.00Price Target Upside188.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Funding RunwayThe substantial financing materially extends the period available to execute the company’s lead program without immediate dependence on another raise. It supports Phase 3, advances adjacent candidates, and gives management greater flexibility to pursue development milestones.
Clinical ProgressRegulatory alignment on a defined registrational study reduces development uncertainty and provides a clearer path toward a potential approval application. Phase 3 advancement also increases the strategic value of EB613 and validates continued investment in the oral peptide platform.
Experienced LeadershipLeadership additions strengthen capabilities that become increasingly important as Entera moves from early development toward Phase 3 execution and commercialization. Relevant experience in clinical, regulatory, and global commercial roles can improve decision-making across the pipeline.
Bears Say
No Commercial RevenueThe absence of meaningful product revenue shows that Entera has not yet established a commercial earnings base. Until a candidate is approved and launched, financial performance will remain dependent on financing, collaborations, and development milestones rather than recurring sales.
Heavy Cash BurnPersistent negative operating and free cash flow means the company is not self-financing its development activities. Continued spending on clinical programs will require substantial cash resources, making future funding access important even after the recent financing.
Ongoing LossesLarge operating losses indicate that the current business model has not yet converted research investment into sustainable profitability. Losses can continue through late-stage trials and commercialization preparation, while negative returns reflect ongoing erosion of shareholder value.
Entera Bio News
ENTX FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was $0.91 and its highest was $4.20 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is $497.42M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Nov 05, 2026 which is in 9 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on Aug 07, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.06.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.07.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 173,922,420 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went up 5.923%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in ENTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (188.18% Upside)
$10.00 (188.18% Upside)
Blogger Sentiment
Bullish
ENTX Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.82%
12-Months-Change
Fundamentals
Return on Equity
-147.19%
Trailing 12-Months
Asset Growth
-0.95%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Entera Bio Ltd
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
ENTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(188.18% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
0.01% Mutual Funds
0.03% Other Institutional Investors
98.62% Public Companies and
Individual Investors